Inter-α inhibitor proteins: a novel therapeutic strategy for experimental anthrax infection

Shock. 2011 Jan;35(1):42-4. doi: 10.1097/SHK.0b013e3181e83204.

Abstract

Human inter-α inhibitor proteins are endogenous human plasma proteins that function as serine protease inhibitors. Inter-α inhibitor proteins can block the systemic release of proteases in sepsis and block furin-mediated assembly of protective antigen, an essential stop in the intracellular delivery of the anthrax exotoxins, lethal toxin and edema toxin. Inter-α inhibitor proteins administered on hour or up to 24 h after spore challenge with Bacillus anthracis Sterne strain protected mice from lethality if administered with antimicrobial therapy (P < 0.001). These human plasma proteins possess combined actions against anthrax as general inhibitors of excess serine proteases in sepsis and specific inhibitors of anthrax toxin assembly. Inter-α inhibitor proteins could represent a novel adjuvant therapy for the treatment of established anthrax infection.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Alpha-Globulins / therapeutic use*
  • Animals
  • Anthrax / drug therapy*
  • Anti-Infective Agents / therapeutic use*
  • Aza Compounds / therapeutic use
  • Bacillus anthracis / drug effects
  • Bacillus anthracis / pathogenicity
  • Fluoroquinolones
  • Humans
  • Liver / microbiology
  • Male
  • Mice
  • Moxifloxacin
  • Quinolines / therapeutic use
  • Spleen / microbiology

Substances

  • Alpha-Globulins
  • Anti-Infective Agents
  • Aza Compounds
  • Fluoroquinolones
  • Quinolines
  • inter-alpha-inhibitor
  • Moxifloxacin